MLTXMoonLake Immunotherapeutics
What is the market doing?
The market is leaning against it: in a downtrend (−34% vs 200-day) and heavily shorted (+13% of shares).
In a downtrend, below its 50- and 200-day averages. Price is −34% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Heavily shorted, settled Sep 15, 2026, about a week of normal trading to cover. Up 25% since the previous count, up from 7.5% of shares outstanding three months ago.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How MLTX is trading
MoonLake Immunotherapeutics is −80% over the past year while the S&P 500 is +18%: 98 points behind the market.
1-year return · S&P 500 +18%
- vs 200-day average
- −34%
vs 200-day average · a clear downtrend
- RSI (14)
- 31
RSI (14) · neutral
- Below its 52-week high
- 83%
Below its 52-week high
Details›
- Last close2026-10-09
- $10.83
- 1 monthS&P 500 +2.7%
- −18%
- 1 yearS&P 500 +18%
- −80%
- 5 yearsS&P 500 +88%
- +9.4%
- vs 50-day average$14.43
- −25%
- 52-week high
- $61.99
- 52-week low
- $6.24
- Annualised volatility
- 91%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- −$2.8M
| Year | Return |
|---|---|
| 2026 (year to date) | −18% |
| 2025 | −76% |
| 2024 | −10% |
| 2023 | +475% |
| 2022 | +6.2% |
| 2021 | −13% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 6 | 2 of 6 | +1.1% |
| Feb | 6 | 3 of 6 | +8.4% |
| Mar | 6 | 4 of 6 | +3.3% |
| Apr | 6 | 1 of 6 | −11% |
| May | 6 | 3 of 6 | +10% |
| Jun | 6 | 5 of 6 | +15% |
| Jul | 6 | 3 of 6 | +5.0% |
| Aug | 6 | 3 of 6 | +4.2% |
| Sep | 6 | 2 of 6 | −18% |
| Oct | 6 | 3 of 6 | +3.8% |
| Nov | 6 | 4 of 6 | +9.9% |
| Dec | 6 | 3 of 6 | +7.9% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.